Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Neurology: Neuroimmunology & Neuroinflammation COVID-19 Article Hub
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

User menu

  • My Alerts
  • Log in
  • Log out

Search

  • Advanced search
Neurology Neuroimmunology & Neuroinflammation
Home
A peer-reviewed clinical and translational neurology open access journal
  • My Alerts
  • Log in
  • Log out
Site Logo
  • Home
  • Articles
  • Issues
  • COVID-19 Article Hub
  • Infographics & Video Summaries

Share

May 2022; 9 (3) Clinical/Scientific NoteOpen Access

Combined Central and Peripheral Demyelination With IgM Anti–Neurofascin 155 Antibodies

Case Report

View ORCID ProfileAntoine Pegat, View ORCID ProfileEmilien Delmont, Juliette Svahn, Emilien Bernard, Lola Lessard, Romain Marignier, View ORCID ProfileFrancoise Bouhour
First published March 21, 2022, DOI: https://doi.org/10.1212/NXI.0000000000001160
Antoine Pegat
From the Service ENMG et Pathologies Neuromusculaires (A.P., J.S., E.B., L.L. F.B.), Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; Centre de référence maladie neuromusculaires et SLA (E.D.), CHU La Timone, APHM, Marseille; Service de neurologie C (J.S., E.B., L.L.), troubles du mouvements et pathologies neuromusculaires, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; and Service de neurologie (R.M.), sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Antoine Pegat
Emilien Delmont
From the Service ENMG et Pathologies Neuromusculaires (A.P., J.S., E.B., L.L. F.B.), Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; Centre de référence maladie neuromusculaires et SLA (E.D.), CHU La Timone, APHM, Marseille; Service de neurologie C (J.S., E.B., L.L.), troubles du mouvements et pathologies neuromusculaires, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; and Service de neurologie (R.M.), sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Emilien Delmont
  • For correspondence: emilien.delmont@ap-hm.fr
Juliette Svahn
From the Service ENMG et Pathologies Neuromusculaires (A.P., J.S., E.B., L.L. F.B.), Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; Centre de référence maladie neuromusculaires et SLA (E.D.), CHU La Timone, APHM, Marseille; Service de neurologie C (J.S., E.B., L.L.), troubles du mouvements et pathologies neuromusculaires, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; and Service de neurologie (R.M.), sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: juliette.svahn@chu-lyon.fr
Emilien Bernard
From the Service ENMG et Pathologies Neuromusculaires (A.P., J.S., E.B., L.L. F.B.), Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; Centre de référence maladie neuromusculaires et SLA (E.D.), CHU La Timone, APHM, Marseille; Service de neurologie C (J.S., E.B., L.L.), troubles du mouvements et pathologies neuromusculaires, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; and Service de neurologie (R.M.), sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: emilien.bernard@chu-lyon.fr
Lola Lessard
From the Service ENMG et Pathologies Neuromusculaires (A.P., J.S., E.B., L.L. F.B.), Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; Centre de référence maladie neuromusculaires et SLA (E.D.), CHU La Timone, APHM, Marseille; Service de neurologie C (J.S., E.B., L.L.), troubles du mouvements et pathologies neuromusculaires, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; and Service de neurologie (R.M.), sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: lola.lessard@chu-lyon.fr
Romain Marignier
From the Service ENMG et Pathologies Neuromusculaires (A.P., J.S., E.B., L.L. F.B.), Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; Centre de référence maladie neuromusculaires et SLA (E.D.), CHU La Timone, APHM, Marseille; Service de neurologie C (J.S., E.B., L.L.), troubles du mouvements et pathologies neuromusculaires, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; and Service de neurologie (R.M.), sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: romain.marignier@chu-lyon.fr
Francoise Bouhour
From the Service ENMG et Pathologies Neuromusculaires (A.P., J.S., E.B., L.L. F.B.), Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; Centre de référence maladie neuromusculaires et SLA (E.D.), CHU La Timone, APHM, Marseille; Service de neurologie C (J.S., E.B., L.L.), troubles du mouvements et pathologies neuromusculaires, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron; and Service de neurologie (R.M.), sclérose en plaques, pathologies de la myéline et neuro-inflammation, Hôpital Neurologique Pierre Wertheimer, Hospices civils de Lyon, Bron, France.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Francoise Bouhour
  • For correspondence: francoise.bouhour@chu-lyon.fr
Full PDF
Citation
Combined Central and Peripheral Demyelination With IgM Anti–Neurofascin 155 Antibodies
Case Report
Antoine Pegat, Emilien Delmont, Juliette Svahn, Emilien Bernard, Lola Lessard, Romain Marignier, Francoise Bouhour
Neurol Neuroimmunol Neuroinflamm May 2022, 9 (3) e1160; DOI: 10.1212/NXI.0000000000001160

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
569

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

Immunoglobulin (Ig) G anti–neurofascin 155 antibodies (anti-NF155 Abs) have been described in rare forms of chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and in combined central and peripheral demyelination (CCPD).1 We report herein a case of a patient presenting CCPD and IgM anti-NF155 Ab.

Case Report

A 43-year-old woman with no medical history was referred to our department for a 3-year history of progressive hand and feet paresthesia, with mild postural and head tremor. She had quadridistal hypesthesia, with ataxic gait, and diffuse diminished tendon reflexes. The Overall Neuropathy Limitations Score (ONLS) was 1/12. Electroneuromyography (ENMG) revealed a diffuse homogeneous demyelinating neuropathy. Nerve ultrasonography and MRI of the cervical plexus (Figure 1, D and E) found a diffuse enlargement of peripheral structures. CSF analysis showed elevated protein level (0.7 g/L, normal <0.4) and 14 white blood cells/mm3 (normal <2) with oligoclonal IgG bands. Cerebral MRI revealed multiple hyperintensities in the periventricular and juxtacortical white matter (diagnosis of radiologically isolated syndrome). All the 97 genes of a panel of genes involved in hereditary neuropathies, especially demyelinating Charcot-Marie-Tooth (CMT), were negative. Peripheral involvement fulfilled the CIDP diagnosis,2 and the patient received 3 monthly IVIg doses (2 g/kg) leading to a subjective improvement of the paresthesia.

Figure 1
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1 Complementary Examinations in Favor of a Combined Central and Peripheral Demyelination Diagnosis

(A) Cerebral MRI fluid-attenuated inversion recovery (FLAIR) images (axial): periventricular and juxtracortical lesions on hypersignal. (B) Cerebral MRI T1 images (axial): black hole lesions on hyposignal. (C) Spine MRI FLAIR images (sagittal): medullar hypersignal in C3, C4, and C5-C6. (D) MRI T2 fat saturation (coronal): bilateral diffuse hyperintensity and diffuse severe hypertrophy of the bilateral brachial plexus. (E) Nerve ultrasonography of the brachial plexus (interscalene): upper, middle trunk enlargement (cross-sectional area [CSA] at 17 mm2; nerve enlargement if CSA >9 mm2).2 (F) Electroneuromyography of the left ulnar nerve: reduced distal compound muscle action potential (CMAP) amplitude at 2.3 mV (normal >4 mV), associated with severe demyelinating abnormalities with prolonged distal motor latency at 11.9 milliseconds (normal <3.6 milliseconds), slow motor conduction velocities at 17 m/s (normal >45 m/s), motor conduction blocks until 62% amplitude reduction at axilla and temporal dispersion, and prolonged distal CMAP duration at 16.4 milliseconds (demyelination if >8.6 milliseconds).2

Eighteen months later, she reported an acute onset (within 3 weeks) of abnormal stiff gait with increased paresthesia in the 4 limbs and tremor. Clinical examination revealed mild spastic paraparesis, with quadridistal weakness (Medical Research Council score between 3 and 4/5 and ONLS score at 4/12). Complementary examinations (Figure 1, A–C and F) revealed increased demyelinating parameters on ENMG, associated with 3 cervical myelitis lesions and new cerebral lesions responding to the multiple sclerosis criteria. A simultaneous peripheral and central relapse of CCPD was diagnosed. The patient presented positive antinuclear antibodies (1/1,280), positive IgM anti-GM3 and GM4 Abs without anti-MAG Abs, and an IgM (lambda) monoclonal gammopathy of undetermined significance (MGUS).

Using flow cytometry (human embryonic kidney cells),3 IgG4 anti-NF155, anti-contactin 1, anti-NF186, and anti-CASPR1 Ab were negative, but IgM anti-NF155 Abs were positive (Figure 2). The patient was treated with 3 monthly IV corticosteroid pulses, with concomitant rituximab treatment (2 infusions of 1 g within 2 weeks and then 1 every 6 months), and experienced a great clinical improvement, as only a mild postural tremor (ONLS at 1/12) remained, without any clinical or radiologic relapse after 2 years of follow-up.

Figure 2
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2 Detection and Monitoring of Anti-NF155 Antibodies in the Blood by Flow Cytometry, Using Human Embryonic Kidney Cells

Antihuman immunoglobulin (Ig) G4 (A) or IgM (B) using fluorescein isothiocyanate (FITC) was used. The mean fluorescence intensity (MFI) is reported in the figure (number per row). In white, a negative control (without IgG4 or IgM antibodies) is shown. In gray, a patient with IgG4 anti-NF155 CIDP (without associated IgM) is shown. In orange, the first sample of a patient positive for IgM anti-NF155 antibody at 2639 MFI (without associated IgG4), and in red, a second sample from the same patient (18 months later), still positive for IgM anti-NF155 antibody at 2799 MFI.

Discussion

We reported herein an instructive case with (1) a peripheral clinical picture of CIDP with ataxia and tremor associated with simultaneous acute relapse of cervical myelitis leading to CCPD diagnosis, (2) a positivity of IgM anti-NF155 Ab without IgG4, and (3) an effectiveness of corticosteroid and rituximab treatment. CIDP associated with IgG4 anti-NF155 Ab is rare (5%–10% of CIDP cases) and presents specific clinical characteristics: young age at onset, distal motor lower limb weakness, sensory ataxia, tremor, poor response to IVIg, and good response to corticosteroids and rituximab.1 NF155 protein is expressed in both the central and peripheral nervous systems explaining the CCPD due to anti-NF155 Ab (up to half the cases of CCPD reported in a Japanese study).1

IgM anti-NF155 Abs have also been rarely described, and their pathogenicity remains unknown. Most IgM anti-NF155 Abs have been associated with IgG4 in patients with neuropathies,3,-,5 but some were found isolated.4,-,7 Isolated IgM anti-NF155 Abs have been reported in only 20 patients: 10 with CIDP (3 with tremor), 2 with Guillain-Barré syndrome, 4 with axonal neuropathies, 2 with CMT, 1 with upper trunk brachial plexopathy, and 1 with facial numbness with normal ENMG, none in CCPD.4,-,7

We are unable to demonstrate a pathophysiologic link between this case of CCPD and IgM anti-NF155 Ab; however, few elements can be discussed. First, the clinical presentation resembles the previously reported cases of CIDP with IgG4 anti-NF155 Ab, notably regarding ataxia, tremor, and associated demyelinating lesion in the CNS,1 although other cases of neuropathies with IgM anti-NF155 Ab have been described with various heterogeneous characteristics.4,-,7 Second, the patient presented an IgM-MGUS, an immune disease, and an antibody with IgM isotype, as in anti-MAG neuropathies, and chronic ataxic neuropathy, ophthalmoplegia, IgM paraprotein, cold agglutinins, and disialosyl antibodies, in which this pathophysiologic link is already known. Finally, an enhancement and prolongation of experimental autoimmune neuritis has been reported in rats after injection of anti-neurofascin IgM, suggesting a pathogenicity of these IgM anti-NF155 Ab.3

In published studies, several techniques have been used to detect IgM anti-NF155 Ab (e.g., cell-based assay [CBA], flow cytometry, ELISA, and Western blot), sometimes with unspecific rat-NF155, which can explain the clinical heterogeneity of patients, especially considering the possible false-positive results.4,-,8 Some authors recommend another confirming technique (e.g., ELISA and immunohistochemistry) associated with CBA (the gold standard technique) because this technique yields a 5.6% false-positive rate in a cohort of 108 patients with inherited neuropathies; in addition, the authors advise against the use of rat-NF155 (leading to false-positive results) and recommend the use of human-NF155.8 Anti-CD20 is a classical treatment of multiple sclerosis and is sometimes effectively used in CIDP, especially with IgG4 anti-NF155, and has been found effective in CCPD.1

Our study presents some limitations. Only 1 method of detection was used without confirming technique. Also, the search for IgM anti-NF155 Ab in the CSF was not performed, neither was nerve biopsy to investigate the presence of disruption of myelin paranodal loops. Moreover, the titers of IgM anti-NF155 Ab remained unchanged after treatment, despite clinical improvement.

In conclusion, this patient presented a CCPD with concomitant peripheral relapse and cervical myelitis leading to find isolated IgM anti-NF155 Ab and responded well to corticosteroids and rituximab. Prospective studies are necessary to demonstrate a pathophysiologic link between IgM anti-NF155 Ab and CCPD and assess the prevalence of this Ab in CCPD.

Study Funding

No targeted funding reported.

Disclosure

The authors report no disclosures relevant to the manuscript. Go to Neurology.org/NN for full disclosures.

Acknowledgment

The authors thank Alexandre Brodovitch for help in preparing the figure on flow cytometry and Hélène Boyer (DRS, Hospices Civils de Lyon) for help in manuscript preparation.

Appendix Authors

Table

Footnotes

  • The Article Processing Charge was funded by Hospices Civils de Lyon (HCL).

  • Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.

  • Received November 2, 2021.
  • Accepted in final form February 8, 2022.
  • Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

References

  1. 1.↵
    1. Wang Z,
    2. Zhou X,
    3. Zhao N,
    4. Xie C,
    5. Zhu D,
    6. Guan Y
    . Neurofascin antibodies in chronic inflammatory demyelinating polyradiculoneuropathy: from intrinsic genetic background to clinical manifestations. Neurol Sci. 2021;42(6):2223-2233. doi:10.1007/s10072-021-05220-3.
    OpenUrlCrossRef
  2. 2.↵
    1. Van den Bergh PYK,
    2. Doorn PA,
    3. Hadden RDM, et al
    . European Academy of Neurology/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint Task Force—second revision. Eur J Neurol. 2021;28(11):3556-3583. doi:10.1111/ene.14959.
    OpenUrlCrossRef
  3. 3.↵
    1. Ng JKM,
    2. Malotka J,
    3. Kawakami N, et al
    . Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology. 2012;79(23):2241-2248. doi:10.1212/WNL.0b013e31827689ad.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Godil J,
    2. Barrett MJ,
    3. Ensrud E,
    4. Chahin N,
    5. Karam C
    . Refractory CIDP: clinical characteristics, antibodies and response to alternative treatment. J Neurol Sci. 2020;418:117098. doi:10.1016/j.jns.2020.117098.
    OpenUrlCrossRef
  5. 5.↵
    1. Burnor E,
    2. Yang L,
    3. Zhou H, et al
    . Neurofascin antibodies in autoimmune, genetic, and idiopathic neuropathies. Neurology. 2018;90(1):e31-e38. doi:10.1212/WNL.0000000000004773.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Doppler K,
    2. Stengel H,
    3. Appeltshauser L, et al
    . Neurofascin-155 IgM autoantibodies in patients with inflammatory neuropathies. J Neurol Neurosurg Psychiatry. 2018;89(11):1145-1151. doi:10.1136/jnnp-2018-318170.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Shelly S,
    2. Klein CJ,
    3. Dyck PJB, et al
    . Neurofascin-155 immunoglobulin subtypes: clinicopathologic associations and neurologic outcomes. Neurology. 2021;97(24):e2392-e2403. doi:10.1212/WNL.0000000000012932.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Martín-Aguilar L,
    2. Pascual-Goñi E,
    3. Lleixà C, et al
    . Antibodies against nodo-paranodal proteins are not present in genetic neuropathies. Neurology. 2020;95(4):e427-e433. doi:10.1212/WNL.0000000000009189.
    OpenUrlAbstract/FREE Full Text

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Case Report
    • Discussion
    • Study Funding
    • Disclosure
    • Acknowledgment
    • Appendix Authors
    • Footnotes
    • References
  • Figures & Data
  • Info & Disclosures
Advertisement

SARS-CoV-2 Vaccination Safety in Guillain-Barré Syndrome, Chronic Inflammatory Demyelinating Polyneuropathy, and Multifocal Motor Neuropathy

Dr. Jeffrey Allen and Dr. Nicholas Purcell

► Watch

Related Articles

  • No related articles found.

Topics Discussed

  • All Immunology
  • All Imaging
  • Multiple sclerosis
  • EMG
  • Chronic inflammatory demyelinating polyneuropathy

Alert Me

  • Alert me when eletters are published
Neurology - Neuroimmunology Neuroinflammation: 10 (3)

Articles

  • Articles
  • Issues
  • Popular Articles

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology: Neuroimmunology & Neuroinflammation
Online ISSN: 2332-7812

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise